期刊
JOURNAL OF CHEMOTHERAPY
卷 19, 期 4, 页码 455-457出版社
ESIFT SRL
DOI: 10.1179/joc.2007.19.4.455
关键词
methotrexate; 5-methyltetrahydrofolate-homocysteine s-methyltransferase; methionine synthase; pollymorphism; genetic; encephalopathy; metabolic; chemotherapy; methionine; folic acid
Methotrexate (MTX) is widely used in the treatment of hematological diseases. The typical side-effects of high-dose MTX chemotherapy on the CNS range from asymptomatic white matter changes to severe CNS demyelination. MTX neurotoxicity has been described to be associated with homocysteline and folate levels as well as genetic variants affecting methionine metabolism. Here we describe a case of severe, acute MTX-induced encephalopathy in a patient who was found to be homozygous for the rare missense variant methionine synthase (MTR) c.2756A>G (D919G), which may have modified the effect of MTX on homocysteine metabolism. This finding encourages further studies to determine to what extent the individual conditions of folate and methionine metabolism influence the effects or side-effects of MTX treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据